A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Summary

This open-label, randomized crossover study evaluated the quality of life, efficacy, and safety of subcutaneous Herceptin (trastuzumab) injected either into the thigh or the upper arm of participants with early HER2-positive breast cancer.

Timeline

Start

2013-09

Primary completion

2013-10

Completion

2013-10

Outcome

Outcome not reported

Stopped: “Problems with drug supply”

Drugs

Indications